COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS

Abstract

results of clinical trials demonstrate that selective vitamin D receptor agonist paricalcitoldecreases proteinuria in patients with chronic kidney disease (CKD) and hyperparathyreosis.

Keywords

• secondary hyperparathyreosis
• nephropathy
• dialysis
• vitamin d receptor agonist
• cost effectiveness analysis
• markov model